Schonfeld Strategic Advisors
Schonfeld Strategic Advisors LLC is a New York-based multi-manager platform that was established in 2015. The firm invests capital with both internal and partner portfolio managers, primarily on an exclusive or semi-exclusive basis, employing a range of strategies including quantitative, fundamental equity, and tactical trading. Schonfeld has a long history of identifying and capitalizing on inefficiencies within the equity markets, leveraging its extensive experience to enhance investment performance. The firm emphasizes a unique structure that grants portfolio managers the autonomy and flexibility necessary to optimize their operations while providing substantial support through proprietary technology, infrastructure, and risk analytics. Its portfolio spans multiple asset classes and geographies, including the Americas, Europe, and Asia.
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.
Bolt is a technology company focused on enhancing e-commerce by providing a streamlined checkout experience. Established in 2014 and based in San Francisco, Bolt aims to democratize commerce by enabling retailers to forge stronger relationships with their customers. The company offers a one-click checkout platform that simplifies the purchasing process, allowing shoppers to complete transactions quickly and securely without the need for passwords or re-entering personal information. This efficiency leads to higher conversion rates for retailers. A diverse range of brands, including REVOLVE, Casper, and Benefit Cosmetics, utilize Bolt's services to deliver the fast and seamless checkout experiences that today's online consumers expect.
Inxeption Corporation is a technology company that operates a cloud-based e-commerce platform tailored for industrial and supply chain businesses. Founded in 2017 and headquartered in South San Francisco, California, Inxeption's platform integrates tools and blockchain technology to facilitate the promotion, sale, and management of products and services online. It offers solutions such as PRODUCT LEDGER, which centralizes and digitizes product information, enabling companies of all sizes to enhance their sales, improve operational visibility, and achieve cost efficiencies. Through the Inxeption B2B marketplace, businesses can access new online commerce channels and applications that streamline logistics and other operations, fostering a more efficient industrial commerce environment.
Innovaccer Inc. develops analytical and data science applications primarily for the healthcare sector, while also serving financial services, manufacturing, retail, and academic research organizations. The company offers a comprehensive Healthcare Intelligence Cloud, which aggregates and analyzes patient data from various sources, including electronic health records and medical devices. This platform enhances patient care and operational efficiency by providing tools for risk adjustment, population health management, and care coordination. Key solutions include Datashop, which features modules for patient insights, economic market analysis, and healthcare trend datasets, as well as a Clinical Documentation Improvement solution to enhance documentation integrity. Innovaccer's offerings also include care navigation, billing, and claims processing tools to streamline operations and improve patient outcomes. The company has established partnerships to further its impact and operates globally from its headquarters in Noida, India, with an office in Palo Alto, California. Founded in 2012, Innovaccer remains committed to transforming healthcare delivery through its innovative technology platform.
Unqork Inc. is a New York-based company that operates a no-code enterprise application platform, designed to assist financial and insurance sectors in managing their client lifecycle. Founded in 2016, Unqork enables organizations to build, deploy, and manage complex applications without the need for traditional coding. This approach allows large enterprises to create custom software more efficiently and at a lower cost compared to conventional methods. The platform not only streamlines the product sales process but also enhances customer experience across various industries, including real estate, government, education, and healthcare. Unqork's innovative solutions significantly improve the quality and speed of software development for its clients.
Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.
AvidXchange, Inc. is a leading provider of accounts payable and payment automation software tailored for midsize businesses across various industries, including healthcare, construction, and real estate. Founded in 2000 and headquartered in Charlotte, North Carolina, AvidXchange offers a comprehensive suite of solutions, including software for purchase orders, invoice management, and payment processing. The company processes over $140 billion in transactions annually through a network of more than 680,000 suppliers, serving approximately 6,000 customers in North America. With a workforce of 1,500 employees and additional offices in several states, AvidXchange continues to innovate and streamline financial operations for its clients, establishing itself as a prominent player in the fintech sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.